The front-runner in Data-Driven Medicine, Sophia Genetics, publicized today how Troy Cox is the most recent member of its Board of Directors.
The Ex-CEO of Foundation Medicine, Troy Cox brings, alongside him to SOPHiA GENETICS, thorough information regarding the biopharmaceutical market
Troy Cox, a precision medicine forerunner, was increasingly committed to improving, at Foundation Medicine, the lives of ailing individuals. This dedication was, in year 2018, acknowledged by the attainment of the firm by Roche. Before Foundation Medicine, Troy Cox acted as the Officer and Senior Vice President at Genentech. At Genentech he headed the U.S. BioOncology for a time span of unparalleled development, partaking in the revel of about half of the goods from the global oncology leader.
Mr. Cox was previously a holder of executive as well as senior posts with a wide range of responsibilities and accomplishments for various healthcare firms. These included Sanofi-Aventis, UCB BioPharmaceuticals, and Schering-Plough.
The co-founder and the chief executive officer of of SOPHiA GENETICS, Jurgi Camblong, personally welcomed Mr. Cox to the team. Jurgi Camblong added how Troy Cox’s thorough experience and prior accomplishments bring considerable finesse to their board of directors. Troy Cox holds the same vision as SOPHiA Genetics in terms of his method for Data-Driven Medication.
Troy Cox stated how he is honored to have a seat on the board of the groundbreaking firm. He says that he is glad to be able to work towards SOPHiA GENETICS’ mission especially since it is what he believes in.